{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:04:47Z","timestamp":1785542687287,"version":"3.56.0"},"reference-count":108,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Colorectal cancer is one of the most common malignancies in the United States as well as a leading cause of cancer-related death. Upward of 30% of patients ultimately develop metastatic disease, most commonly to the liver and lung. Untreated, patients have poor survival. Historically, patients with oligometastatic disease were treated with resection leading to long-term survival; however, there are many patients who are not surgical candidates. Innovations in thermal ablation, hepatic artery infusions, chemoembolization and radioembolization, and stereotactic ablative radiation have led to an expansion of patients eligible for local therapy. This review examines the evidence behind each modality for the most common locations of oligometastatic colorectal cancer.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000729","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T08:09:17Z","timestamp":1721722157000},"page":"272-279","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Local-Regional Therapy for Oligometastatic Colorectal Cancer"],"prefix":"10.1097","volume":"30","author":[{"given":"Sean R.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-1554","authenticated-orcid":false,"given":"Daniel T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250928","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250928","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","article-title":"Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases","volume":"32","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"bib3-20250928","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/bjs5.50299","article-title":"Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study","volume":"4","year":"2020","journal-title":"BJS Open"},{"key":"bib4-20250928","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","year":"1995","journal-title":"J Clin Oncol"},{"key":"bib5-20250928","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/bjs.5278","article-title":"A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer","volume":"93","year":"2006","journal-title":"Br J Surg"},{"key":"bib6-20250928","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.sla.0000217629.94941.cf","article-title":"Epidemiology and management of liver metastases from colorectal cancer","volume":"244","year":"2006","journal-title":"Ann Surg"},{"key":"bib7-20250928","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1097-0142(197009)26:3<493::AID-CNCR2820260302>3.0.CO;2-7","article-title":"Survival after liver resection for cancer","volume":"26","year":"1970","journal-title":"Cancer"},{"key":"bib8-20250928","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archsurg.1976.01360220026004","article-title":"Surgical treatment of hepatic metastases from colorectal cancers","volume":"111","year":"1976","journal-title":"Arch Surg"},{"key":"bib9-20250928","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00000658-198405000-00002","article-title":"The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment","volume":"199","year":"1984","journal-title":"Ann Surg"},{"key":"bib10-20250928","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/bjs.1800771115","article-title":"Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history","volume":"77","year":"1990","journal-title":"Br J Surg"},{"key":"bib11-20250928","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/annonc\/mdq043","article-title":"Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer\u2014an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009","volume":"21","year":"2010","journal-title":"Ann Oncol"},{"key":"bib12-20250928","first-page":"283","article-title":"Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors","volume":"4","year":"2012","journal-title":"Clin Epidemiol"},{"key":"bib13-20250928","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/01.sla.0000145965.86383.89","article-title":"A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases","volume":"240","year":"2004","journal-title":"Ann Surg"},{"key":"bib14-20250928","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejso.2006.10.038","article-title":"Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases","volume":"33","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"bib15-20250928","doi-asserted-by":"crossref","first-page":"699","DOI":"10.5009\/gnl19233","article-title":"Associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) registry: what have we learned?","volume":"14","year":"2020","journal-title":"Gut Liver"},{"key":"bib16-20250928","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/SLA.0000000000003701","article-title":"ALPPS improves survival compared with TSH in patients affected of CRLM: survival analysis from the randomized controlled trial LIGRO","volume":"273","year":"2021","journal-title":"Ann Surg"},{"key":"bib17-20250928","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","article-title":"Liver transplantation for nonresectable liver metastases from colorectal cancer","volume":"257","year":"2013","journal-title":"Ann Surg"},{"key":"bib18-20250928","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","year":"1999","journal-title":"Ann Surg"},{"key":"bib19-20250928","doi-asserted-by":"crossref","first-page":"e232932","DOI":"10.1001\/jamasurg.2023.2932","article-title":"Long-term survival, prognostic factors, and selection of patients with colorectal cancer for liver transplant: a nonrandomized controlled trial","volume":"158","year":"2023","journal-title":"JAMA Surg"},{"key":"bib20-20250928","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12957-015-0621-7","article-title":"The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer","volume":"13","year":"2015","journal-title":"World J Surg Oncol"},{"key":"bib21-20250928","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1245\/s10434-012-2726-3","article-title":"Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis","volume":"20","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"bib22-20250928","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/codi.15113","article-title":"Pulmonary metastasectomy in colorectal cancer: updated analysis of 93 randomized patients\u2014control survival is much better than previously assumed","volume":"22","year":"2020","journal-title":"Colorectal Dis"},{"key":"bib23-20250928","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/bmj.306.6880.752","article-title":"Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer","volume":"306","year":"1993","journal-title":"BMJ"},{"key":"bib24-20250928","doi-asserted-by":"crossref","first-page":"49","DOI":"10.21037\/hbsn.2019.06.08","article-title":"Role of thermal ablation in the management of colorectal liver metastasis","volume":"9","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"bib25-20250928","first-page":"djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"bib26-20250928","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1186\/s12885-018-4716-8","article-title":"Colorectal liver metastases: surgery versus thermal ablation (COLLISION)\u2014a phase III single-blind prospective randomized controlled trial","volume":"18","year":"2018","journal-title":"BMC Cancer"},{"key":"bib27-20250928","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jvir.2017.08.021","article-title":"Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control","volume":"29","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"bib28-20250928","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.hpb.2018.05.012","article-title":"A comparison of microwave thermosphere versus radiofrequency thermal ablation in the treatment of colorectal liver metastases","volume":"20","year":"2018","journal-title":"HPB"},{"key":"bib29-20250928","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ejso.2019.12.003","article-title":"Systematic review and meta-analysis of local ablative therapies for resectable colorectal liver metastases","volume":"46","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"bib30-20250928","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2023.03.038","article-title":"A prospective multicentre trial on survival after microwave ablation versus resection for resectable colorectal liver metastases (MAVERRIC)","volume":"187","year":"2023","journal-title":"Eur J Cancer"},{"key":"bib31-20250928","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41598-021-03802-x","article-title":"Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial","volume":"12","year":"2022","journal-title":"Sci Rep"},{"key":"bib32-20250928","first-page":"107","article-title":"Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo","volume":"12","year":"1951","journal-title":"J Natl Cancer Inst"},{"key":"bib33-20250928","first-page":"176","article-title":"Clinical pharmacology of hepatic arterial chemotherapy","volume":"10","year":"1983","journal-title":"Semin Oncol"},{"issue":"11 Pt 1","key":"bib34-20250928","first-page":"3784","article-title":"A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2\u2032-deoxyuridine and 5-fluorouracil","volume":"38","year":"1978","journal-title":"Cancer Res"},{"key":"bib35-20250928","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","article-title":"Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer","volume":"341","year":"1999","journal-title":"N Engl J Med"},{"key":"bib36-20250928","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM200502173520723","article-title":"Hepatic arterial infusion after liver resection","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"bib37-20250928","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.2016.71.8346","article-title":"Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib38-20250928","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/jso.25916","article-title":"Addition of adjuvant hepatic artery infusion to systemic chemotherapy following resection of colorectal liver metastases is associated with reduced liver-related mortality","volume":"121","year":"2020","journal-title":"J Surg Oncol"},{"key":"bib39-20250928","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.hpb.2019.11.013","article-title":"The impact of hepatic arterial infusion pump chemotherapy on hepatic recurrences and survival in patients with resected colorectal liver metastases","volume":"22","year":"2020","journal-title":"HPB"},{"key":"bib40-20250928","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jso.24898","article-title":"Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential","volume":"117","year":"2018","journal-title":"J Surg Oncol"},{"key":"bib41-20250928","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib42-20250928","first-page":"133","article-title":"Locoregional therapies for colorectal cancer liver metastases: options beyond resection","volume":"41","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"bib43-20250928","first-page":"1387","article-title":"Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study","volume":"32","year":"2012","journal-title":"Anticancer Res"},{"key":"bib44-20250928","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/cncr.29534","article-title":"Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis","volume":"121","year":"2015","journal-title":"Cancer"},{"key":"bib45-20250928","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/bjs\/znaa155","article-title":"Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial","volume":"108","year":"2021","journal-title":"Br J Surg"},{"key":"bib46-20250928","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: randomized phase III trial comparing first-Line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal Cancer","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib47-20250928","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib48-20250928","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jvir.2022.12.021","article-title":"Yttrium-90 radiation segmentectomy in oligometastatic secondary hepatic malignancies","volume":"34","year":"2023","journal-title":"J Vasc Interv Radiol"},{"key":"bib49-20250928","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib50-20250928","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib51-20250928","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib52-20250928","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0360-3016(94)00591-8","article-title":"The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy","volume":"32","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib53-20250928","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/0360-3016(92)90651-W","article-title":"The use of 3-D dose volume analysis to predict radiation hepatitis","volume":"23","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib54-20250928","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1062::AID-CNCR8>3.0.CO;2-G","article-title":"Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience","volume":"82","year":"1998","journal-title":"Cancer"},{"key":"bib55-20250928","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","year":"2010","journal-title":"JAMA"},{"key":"bib56-20250928","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.2001.19.1.164","article-title":"Stereotactic single-dose radiation therapy of liver tumors: results of a phase I\/II trial","volume":"19","year":"2001","journal-title":"J Clin Oncol"},{"key":"bib57-20250928","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02841860600904854","article-title":"Phase II study on stereotactic body radiotherapy of colorectal metastases","volume":"45","year":"2006","journal-title":"Acta Oncol"},{"key":"bib58-20250928","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1002\/cncr.25997","article-title":"Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis","volume":"117","year":"2011","journal-title":"Cancer"},{"key":"bib59-20250928","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/1471-2407-14-619","article-title":"Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach","volume":"14","year":"2014","journal-title":"BMC Cancer"},{"key":"bib60-20250928","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijrobp.2008.03.062","article-title":"Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy","volume":"73","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib61-20250928","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","year":"2018","journal-title":"BMC Cancer"},{"key":"bib62-20250928","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","article-title":"Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer","volume":"99","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib63-20250928","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.radonc.2011.05.033","article-title":"Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer","volume":"101","year":"2011","journal-title":"Radiother Oncol"},{"key":"bib64-20250928","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib65-20250928","article-title":"Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype","volume":"109","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"bib66-20250928","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijrobp.2017.04.010","article-title":"Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases","volume":"99","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib67-20250928","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ijrobp.2005.01.002","article-title":"A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases","volume":"62","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib68-20250928","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.prro.2017.03.004","article-title":"Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy","volume":"7","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"bib69-20250928","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijrobp.2005.07.002","article-title":"Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer","volume":"63","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib70-20250928","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","article-title":"Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer","volume":"72","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib71-20250928","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cncr.24059","article-title":"Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas","volume":"115","year":"2009","journal-title":"Cancer"},{"issue":"3 Suppl","key":"bib72-20250928","first-page":"S101","article-title":"Radiation dose-volume effects in the stomach and small bowel","volume":"76","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib73-20250928","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.radonc.2016.10.024","article-title":"Central liver toxicity after SBRT: an expanded analysis and predictive nomogram","volume":"122","year":"2017","journal-title":"Radiother Oncol"},{"key":"bib74-20250928","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2022.09.003","article-title":"A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases","volume":"176","year":"2022","journal-title":"Radiother Oncol"},{"key":"bib75-20250928","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ijrobp.2017.12.014","article-title":"Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases","volume":"100","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib76-20250928","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00432-018-2692-7","article-title":"Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation","volume":"144","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"bib77-20250928","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1148\/radiol.2020191272","article-title":"Three-year survival rate after radiofrequency ablation for surgically Resectable colorectal lung metastases: a prospective multicenter study","volume":"294","year":"2020","journal-title":"Radiology"},{"key":"bib78-20250928","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1245\/s10434-006-9101-1","article-title":"Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival","volume":"13","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"bib79-20250928","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1148\/radiol.2431060088","article-title":"Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients","volume":"243","year":"2007","journal-title":"Radiology"},{"key":"bib80-20250928","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jvir.2007.06.027","article-title":"Percutaneous radiofrequency ablation for pulmonary metastases from colorectal cancer: midterm results in 27 patients","volume":"18","year":"2007","journal-title":"J Vasc Interv Radiol"},{"key":"bib81-20250928","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jvir.2006.11.003","article-title":"Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan","volume":"18","year":"2007","journal-title":"J Vasc Interv Radiol"},{"key":"bib82-20250928","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00270-012-0500-3","article-title":"Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases","volume":"36","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"bib83-20250928","first-page":"37","article-title":"Treatment of pulmonary colorectal metastases by radiofrequency ablation","volume":"12","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"bib84-20250928","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s10147-018-1357-5","article-title":"CT-guided percutaneous radiofrequency ablation for lung metastases from colorectal cancer","volume":"24","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"bib85-20250928","doi-asserted-by":"crossref","first-page":"943715","DOI":"10.3389\/fonc.2022.943715","article-title":"Long-term outcome following microwave ablation of lung metastases from colorectal cancer","volume":"12","year":"2022","journal-title":"Front Oncol"},{"key":"bib86-20250928","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2214\/AJR.15.14401","article-title":"Thermal ablation of colorectal lung metastases: retrospective comparison among laser-induced thermotherapy, radiofrequency ablation, and microwave ablation","volume":"207","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"bib87-20250928","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2021.10.023","article-title":"A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ablative radiotherapy use in lung metastases from colon-rectal cancer: the LaIT-SABR study","volume":"166","year":"2022","journal-title":"Radiother Oncol"},{"key":"bib88-20250928","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12885-019-5362-5","article-title":"The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases","volume":"19","year":"2019","journal-title":"BMC Cancer"},{"key":"bib89-20250928","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2407-3-26","article-title":"Follow-up of patients with curatively resected colorectal cancer: a practice guideline","volume":"3","year":"2003","journal-title":"BMC Cancer"},{"key":"bib90-20250928","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jso.20926","article-title":"Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma","volume":"97","year":"2008","journal-title":"J Surg Oncol"},{"key":"bib91-20250928","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4174\/astr.2020.98.3.130","article-title":"Management of isolated para-aortic lymph node recurrence after surgery for colorectal cancer","volume":"98","year":"2020","journal-title":"Ann Surg Treat Res"},{"key":"bib92-20250928","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10350-004-6300-3","article-title":"Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma","volume":"45","year":"2002","journal-title":"Dis Colon Rectum"},{"key":"bib93-20250928","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/BF02049858","article-title":"Surgical management of nonhepatic intra-abdominal recurrence of carcinoma of the colon","volume":"36","year":"1993","journal-title":"Dis Colon Rectum"},{"key":"bib94-20250928","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1245\/s10434-014-4363-5","article-title":"Incorporation of radiotherapy in the multidisciplinary treatment of isolated retroperitoneal lymph node recurrence from colorectal cancer","volume":"22","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"bib95-20250928","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.radonc.2010.05.021","article-title":"Curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer","volume":"97","year":"2010","journal-title":"Radiother Oncol"},{"key":"bib96-20250928","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jjco\/hyn083","article-title":"Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma","volume":"38","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"bib97-20250928","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.3748\/wjg.15.6091","article-title":"Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer","volume":"15","year":"2009","journal-title":"World J Gastroenterol"},{"key":"bib98-20250928","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.prro.2014.09.006","article-title":"Stereotactic body radiation therapy for abdominal and pelvic oligometastases: dosimetric targets for safe and effective local control","volume":"5","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"bib99-20250928","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/1754-9485.13057","article-title":"Overall and chemotherapy-free survival following stereotactic body radiation therapy for abdominopelvic oligometastases","volume":"64","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"key":"bib100-20250928","doi-asserted-by":"crossref","first-page":"20170422","DOI":"10.1259\/bjr.20170422","article-title":"Stereotactic\/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis","volume":"90","year":"2017","journal-title":"Br J Radiol"},{"key":"bib101-20250928","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2020.06.029","article-title":"Assessing the role of stereotactic body radiation therapy in a large cohort of patients with lymph node oligometastases: does it affect systemic treatment's intensification?","volume":"150","year":"2020","journal-title":"Radiother Oncol"},{"key":"bib102-20250928","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10585-018-9922-x","article-title":"Locoregional control and survival after lymph node SBRT in oligometastatic disease","volume":"35","year":"2018","journal-title":"Clin Exp Metastasis"},{"key":"bib103-20250928","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12885-020-07033-7","article-title":"Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal\/pelvic lymph nodes: a retrospective study","volume":"20","year":"2020","journal-title":"BMC Cancer"},{"key":"bib104-20250928","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/COC.0b013e3182610878","article-title":"Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer","volume":"37","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"bib106-20250928","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1002\/cncr.34931","article-title":"American radium society appropriate use criteria for the use of liver-directed therapies for nonsurgical management of liver metastases: systematic review and guidelines","volume":"129","year":"2023","journal-title":"Cancer"},{"key":"bib107-20250928","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib108-20250928","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial\u2014a prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","year":"2021","journal-title":"J Thorac Oncol"},{"key":"bib109-20250928","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:00:55Z","timestamp":1759042855000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000729","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}